MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly

• Published in: Vaccine Vol. 40; no. 10; pp. 1472 - 1482
• Main Authors: Gorse, Geoffrey J., Grimes, Stephen, Buck, Helen, Mulla, Hussain, White, Peter, Hill, Heather, May, Jeanine, Frey, Sharon E., Blackburn, Peter
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.03.2022; Elsevier Limited
• Subjects: Adjuvant; Adjuvants; Adjuvants, Immunologic; Aged; Aged, 80 and over; Allergy and Immunology; Alzheimer's disease; Antibodies; Antibodies, Viral; Antibody Formation; Antigens; Blood; blood serum; Clinical trials; cross reaction; Cross-reactivity; Dosage; Durability; elderly; Guillain-Barre syndrome; Headache; Health care; hemagglutination; Hemagglutination inhibition; Hemagglutination inhibition antibody; Hemagglutination Inhibition Tests; Hemagglutinins; Humans; Hypotheses; Immunogenicity; Influenza; Influenza vaccine; Influenza Vaccines; Influenza, Human; Injection; injection site; Laboratories; Morbidity; mortality; Myalgia; Older people; Reactogenicity; Safety; Seasons; Seroconversion; Urinalysis; Vaccination; Vaccine efficacy; Vaccines; Water; Thailand; Phuket Thailand; CRP; FDA; CDC; T1D; GMFI; ALT; DT; Hemagglutination inhibition antibody; SD; WBC; Adjuvant; Influenza vaccine; AST; ISR; Physical examination; GMT; HAI; Immunogenicity; IIV; MAS-1; HA; HD; Reactogenicity; CPK; QIV; hemagglutination inhibition; C-reactive protein; hemagglutinin; alanine aminotransferase; geometric mean fold increase; injection site reaction; geometric mean titer; Centers for Disease Control and Prevention; quadrivalent inactivated influenza vaccine; Mercia adjuvant system-1; standard dose; Type 1 diabetes mellitus; Diphtheria toxoid; white blood cell; creatine phosphokinase; U.S. Food and Drug Administration; inactivated influenza virus vaccine; high dose; PE; aspartate amino transferase

•MAS-1 adjuvant with 9 µg per hemagglutinin in 0.3 mL was safe and immunogenic in the elderly.•Antibodies to adjuvanted vaccine peaked by 85 days and were durable at 169 days.•Responses to adjuvanted vaccine appeared better than high dose influenza vaccine.•Adjuvanted vaccine induced seroresponses t...